Sigyn Therapeutics, Inc. (OTCQB: SIGY), developer of CardioDialysis, a next-generation blood purification technology, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). In the United States, CTE has been most commonly diagnosed in former NFL players through post-mortem autopsy.
On March 21, Scientific American published an article entitled “Brain’s Protective Barrier Stays Leaky for Years after Playing Contact Sports,” coinciding with a study released in the journal Science Translational Medicine. The study reported that the blood-brain barrier may remain compromised and permeable for decades following an athlete’s retirement from sports involving repetitive head trauma.
When the integrity of the blood-brain barrier becomes compromised, inflammatory molecules and pathogenic toxins in the bloodstream are able to enter the brain. The resulting neuroinflammation can trigger a cascade of damaging processes, including the abnormal accumulation of tau protein, a hallmark indicator of CTE. Researchers further observed that the former athletes enrolled in the study appeared to exist in a persistent state of chronic hyperinflammation.
The Trinity study adds to a growing body of evidence indicating that systemic (bloodstream) inflammation is a key driver of neuroinflammation associated with the progression of disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Given its broad-spectrum mechanism, CardioDialysis is uniquely positioned to emerge as a potential adjunct therapy for neuroinflammatory conditions.
As previously disclosed, Sigyn Therapeutics is pursuing a strategic transaction focused on the use of CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI). The Company’s lead clinical indication for CardioDialysis remains the treatment of cardiovascular disease, the leading cause of death worldwide.
“It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease,” stated Sigyn Therapeutics CEO Jim Joyce. “The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain,” Joyce concluded.
The following link provides access to the Scientific American article: https://www.scientificamerican.com/article/brains-protective-barrier-stays-leaky-for-years-after-playing-contact-sports/.
